Acute rejection of renal allografts: Mechanistic insights and therapeutic options

Kidney International

Volumn 51, Issue 4, 1997, Pages 1289-1304

  Suthanthiran, Manikkam ^a  

^a WEILL CORNELL MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

15 DEOXYSPERGUALIN; AZATHIOPRINE; CYCLOSPORIN A; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 2; MIZORIBINE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; TACROLIMUS;

ADULT; CASE REPORT; FEMALE; GRAFT REJECTION; HUMAN; KIDNEY TRANSPLANTATION; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; REVIEW;

EID: 0030984291     PISSN: 00852538     EISSN: None     Source Type: Journal    
DOI: 10.1038/ki.1997.176     Document Type: Article

References (182)

1. CECKA JM, TERASAKI PI: The UNOS Scientific Renal Transplant Registry, in Clinical Transplants 1994, edited by TURASAKI PI, CECKA JM, Los Angeles, UCLA Tissue Typing Laboratory, 1995, pp 1-18
2. SUTHANTHIRAN M, STROM TB: Renal transplantation. N Engl J Med 331:365-376, 1994
3. FEDUSKA NJ, CECKA JM: Donor factors, in Clinical Transplants 1994, edited by TERASAKI PI, CECKA JM, Los Angeles, UCLA Tissue Typing Laboratory, 1995, pp 381-394
4. TERASAKI PI, CECKA JM, GJERTSON DW, TAKEMOTO S: High survival rates of kidney transplants from spousal and living unrelated donors. N Engl J Med 333:333-336, 1995
5. CECKA JM, TERASAKI PI: The UNOS Scientific Renal Transplant Registry, in Clinical Transplants 1992, edited by TERASAKI PI, CECKA JM, Los Angeles, UCLA Tissue Typing Laboratory, 1993, pp 1-16
6. ALMOND PS, MATAS A, GILLINGHAM KJ, DUNN DL, PAYNE WD, GORES P, GRUESSNER R, NAJARIAN JS: Risk factors for chronic rejection in renal allograft recipients. Transplantation 55:752-757, 1993
7. BIA MJ: Nephrology Forum: Nonimmunologic causes of late renal graft loss. Kidney Int 47:1470-1480, 1995
8. TILNEY NL, STROM TB, VINEYARD GC, MERRILL JP: Factors contributing to the declining mortality rate in renal transplantation. N Engl J Med 299:1321-1325, 1978
9. CHEIGH JS, FOTINO M, STUBENBORD WT, SUTHANTHIRAN M, RIGGIO RR, SAAL SD: Declining transplantability of prospective kidney transplant recipients. JAMA 246:135-139, 1981
10. SANFILLIPPO F, VAUGHN WK, BOLLINGER RR, SPEES EK: Comparative effects of pregnancy, transfusion and prior graft rejection on sensitization and renal transplant results. Transplantation 34:360-366, 1982
11. STROM TB, SUTHANTHIRAN M: Therapeutic approach to organ transplantation, in Therapeutic Immunology (chapter 36), edited by AUSTEN KF, BURAKOFF SJ, ROSEN FS, STROM TB, London, Blackwell Scientific, 1996, pp 451-456
12. SUTHANTHIRAN M, CHEIGH JS, MOURADIAN JK, STENZEL KH: Diagnosis and treatment of rejection, in The Principles and Practice of Nephrology (2nd ed), edited by JACOBSON HR, STRIKER GE, KLAHR S, St. Louis, Mosby, 1994, pp 838-841
13. SOLEZ K, AXELSEN RA, BENEDIKTSSON H, BURDICK JF, COHEN AH, COLVIN RB, CROKER BP, DROZ D, DUNNILL MS, HALLORAN PF, HÄYRY P, JENNETTE JC, KEOWN PA, MARCUSSEN N, MIHATSCH MJ, MOROZUMI K, MYERS D, NAST CC, OLSEN S, RACUSEN LC, RAMOS EL, ROSEN S, SACHS DH, SALOMON DR, SANFILIPPO F, VERANI R, VON WILLEBRAND E, YAMAGUCHI Y: International standardization of criteria for the histologic diagnosis of renal allograft rejection: The Banff working classification of kidney transplant pathology. Kidney Int 44:411-422, 1993
14. KAHAN BD: Cyclosporine. N Engl J Med 321:1725-1738, 1989
15. UNANUE ER, CEROTTONI J-C: Antigen presentation. FASEB J 3:2496-2502, 1989
16. GERMAIN RN: MHC-dependent antigen processing and peptide presentation: providing ligands for T lymphocyte activation. Cell 76:287-299, 1994
17. SHOSKES DA, WOOD KJ: Indirect presentation of MHC antigens in transplantation. Immunol Today 15:32-38, 1994
18. WEISS A, LITTMAN DR: Signal transduction by lymphocyte antigen receptors. Cell 76:263-264, 1994
19. CLEVERS H, ALARCON B, WILEMAN T, TERHORST C: The T cell receptor/CD3 complex: a dynamic protein ensemble. Annu Rev Immunol 6:629-662, 1988
20. MICELI MC, PARNES JR: The role of CD4 and CD8 in T-cell activation. Semin Immunol 3:133-141, 1991
21. SUTHANTHIRAN M: A novel model for antigen-dependent activation of normal human T-cells. Transmembrane signaling by crosslinkage of the CD3/T cell receptor-α/β complex with the cluster determinant 2 antigen. J Exp Med 171:1965-1979, 1990
22. BROWN MH, CANTRELL DA, BRATTSAND G, CRUMPTON MJ, GULLBERG M: The CD2 antigen associates with the T-cell antigen receptor/CD3/antigen complex on the surface of human T lymphocytes. Nature 339:551-553, 1989
23. BEYERS AD, SPRUYT LL, WILLIAMS AF: Molecular associations between the T-lymphocyte antigen receptor complex and the surface antigens CD2, CD4, or CD8 and CD5. Proc Natl Acad Sci USA 89:2945-2949, 1992
24. KLAUSNER RD, SAMELSON LE: T-cell antigen receptor activation pathways: the tyrosine kinase connection. Cell 64:875-878, 1991
25. NISHIZUKA Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258:607-614, 1992
26. O'KEEFE SJ, TAMURA J, KINCAID RL, TOCCI MJ, O'NEILL EA: FK506- and CsA-sensitive activation of the interleukin-2 promoter by calcineurin. Nature 357:692-694, 1992
27. CLIPSTONE NA, CRABTREE GR: Identification of calcineurin as a key signalling enzyme in T-lymphocyte activation. Nature 357:695-697, 1992
28. LIU J, FARMER JD JR, LANE WS, FRIEDMAN J, WEISSMAN I, SCHREIBER SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes. Cell 66:807-815, 1991
29. FRUMAN DA, KLEE CB, BIERER BE, BURAKOFF SJ: Calcineurin phosphatase activity in T lymphocytes is inhibited by FK506 and cyclosporin A. Proc Natl Acad Sci USA 89:3686-3690, 1992
30. JENKINS MK, SCHWARTZ RH: Antigen presentation by chemically modified splenocytes induces antigen-specific T cell unresponsiveness in vitro and in vivo. J Exp Med 165:302-319, 1987
31. SCHWARTZ RH: Models of T cell anergy: Is there a common molecular mechanism? J Exp Med 184:1-8, 1996
32. SUTHANTHIRAN M: Signaling features of T-cells: Implications for the regulation of the anti-allograft response. Kidney Int 44(Suppl 43):S3-S11, 1993
33. DUSTIN ML, SPRINGER TA: T-cell receptor crosslinking transiently stimulates adhesiveness through LFA-1. Nature 341:619-624, 1989
34. JUNE CH, LEDBETTER JA, LINSLEY PS, THOMPSON CB: Role of the CD28 receptor in T-cell activation. Immunol Today 11:211-216, 1990
35. LINSLEY PS, BRADY W, URNES M, GROSMAIRE LS, DAMLE NK, LEDBETTER JA: CTLA-4 is a second receptor for the B-cell activation antigen B7. J Exp Med 174:561-569, 1991
36. THOMPSON CB, LINDSTEN T, LEDBETTER JA, KUNKEL SL, YOUNG HA, EMERSON SG, LEIDEN JM, JUNE CH: CD28 activation pathway regulates the production of multiple T-cell-derived lymphokines/ cytokines. Proc Natl Acad Sci USA 86:1333-1337, 1989
37. ALLISON JP, KRUMMEL MF: The yin and yang of T cell costimulation. Science 270:932-933, 1995
38. ISOBE M, YAGITA H, OKUMURA K, IHARA A: Specific acceptance of cardiac allograft after treatment with antibodies to ICAM-1 and LFA-1. Science 255:1125-1127, 1992
39. LENSCHOW J, ZENG Y, THISTLETHWAITE R, MONTAG A, BRADY W, GIBSON MG, LINSLEY PS, BLUESTONE JA: Long-term survival of xenogeneic pancreatic islet grafts induced by CTLA-4Ig. Science 257:789-792, 1992
40. KAPUR S, KHANNA A, SHARMA VK, LI B, SUTHANTHIRAN M: CD2 antigen targeting reduces intragraft expression of mRNA encoding granzyme B and IL-10 and induces tolerance. Transplantation 62: 249-255, 1996
41. WILLIAMS JM, DELORIA D, HANSEN JA, DINARELLO CA, LOERTSCHER R, SHAPIRO HM, STROM TB: The events of primary T-cell activation can be staged by use of sepharose-bound anti-T3 [64.1] monoclonal antibody and purified interleukin-1. J Immunol 135: 2249-2255, 1985
42. BRETCHER P, COHEN M: A theory of self-nonself discrimination: Paralysis and induction involve the recognition of one and two determinants on an antigen, respectively. Science 169:1042-1049, 1970
43. CLARK EA, LEDBETTER JA: How B- and T-cells talk to each other. Nature 367:425-428, 1994
44. STROM TB, TILNEY NL, CARPENTER CB, BUSCH GJ: Identity and cytotoxic capacity of cells infiltrating renal allografts. N Engl J Med 292:1257-1263, 1975
45. SUTHANTHIRAN M, GAROVOY MR: Immunologic monitoring of the renal allograft recipient. Urol Clin North Am 10:315-325, 1983
46. SAIKI RK, GELFAND DH, STOFFEL S, SCHARF SJ, HIGUCHI R, HORN GT, MULLIS KB, ERLICH HA: Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science 239:487-491, 1988
47. RAPPOLEE D, MARK D, BANDA MJ, WERB Z: Wound macrophages express TGF-α and other growth factors in vivo: analysis by mRNA phenotyping. Science 241:708-712, 1988
48. LIPMAN ML, STEVENS AC, BLEACKLEY RC, HELDERMAN JH, MCCUNE TR, HARMON WE, SHAPIRO ME, ROSEN S, STROM TB: The strong correlation of cytotoxic T lymphocyte specific serine protease gene transcripts with renal allograft rejection. Transplantation 53:73-79, 1992
49. LIPMAN ML, STEVENS AC, STROM TB: Heightened intragraft cytotoxic T lymphocyte gene expression in acutely rejecting renal allografts. J Immunol 152:5120-5127, 1994
50. XU G-P, SHARMA VK, LI B, BOLOGA R, LI Y, MOURADIAN J, WANG J, SERUR D, RAO V, STENZEL KH, SUTHANTHIRAN M: Intragraft expression of IL-10 messenger RNA: A novel correlate of renal allograft rejection. Kidney Int 48:1504-1507, 1995
51. 1 mRNA: A correlate of interstitial fibrosis and chronic allograft nephropathy. Kidney Int 49:1297-1303, 1996
52. DALLMAN M, ROAKE J, HUGHES D, TOOGOOD G, MORRIS P: Sequential analysis of IL-2 gene transcription in renal transplants. Transplantation 53:683-685, 1992
53. NAST CC, XIAO-JING Z, PREHN J, DANOVITCH GM, WILKINSON A, JORDAN SC: Gamma-interferon gene expression in human renal allograft fine-needle aspirates. Transplantation 57:498-502, 1994
54. STROM TB, TILNEY NL, PARADYSZ JM, BANCEWICZ J, CARPENTER CB: Cellular components of allograft rejection: identity, specificity and cytotoxic function of cells infiltrating acutely rejecting allografts. J Immunol 118:2020-2026, 1977
55. LOBE CG, FINLAY BB, PARANCHYCH W, PAETKAU VH, BLEACKLEY RC: Novel serine proteases encoded by two cytotoxic T lymphocyte-specific genes. Science 232:858-661, 1986
56. LOBE CG, HAVELE C, BLEACKLEY RC: Cloning of two genes that are specifically expressed in activated cytotoxic T lymphocytes. Proc Natl Acad Sci USA 83:1448-1452, 1986
57. BLEACKLEY RC, LOBE CG, DUGGAN B, EHRMAN N, FREGEAU C, MEIER M, LETELLIER M, HAVELE C, SHAW J, PAETKAU V: The isolation and characterization of a family of serine protease genes expressed in activated cytotoxic T lymphocytes. Immunol Rev 103:5-19, 1988
58. MASSON D, TSCHOPP J: A family of serine esterases in lytic granules of cytolytic T lymphoctyes. Cell 49:679-685, 1987
59. GARCIA-SANZ JA, MACDONALD HR, JENNE DE, TSCHOPP J, NABHOLZ M: Cell specificity of granzyme gene expression. J Immunol 145:3111-3118, 1990
60. HEUSEL JW, WESSELSCHMIDT RL, SHRESTA S, RUSSELL JH, LEY TJ: Cytotoxic lymphocytes require granzyme B for the rapid induction of DNA fragmentation and apoptosis in allogeneic target cells. Cell 76:977-987, 1994
61. YOUNG JD, LIU CC, LEONG LG, COHN ZA: The pore-forming protein (perforin) of cytotoxic T lymphocytes is immunologically related to the components of membrane attack complex of complement through cysteine rich domains. J Exp Med 164:2077-2082, 1986
62. LICHTENHELD MG, OLSEN KJ, LU P, LOWREY DM, JAMEED A, HENGARTNER H, PODACK ER: Structure and function of human perforin. Nature 335:448-451, 1988
63. ACHA-ORBEA H, SCARPELLINO L, HERTIG S, DUPUIS M, TSCHOPP J: Inhibition of lymphocyte mediated cytotoxicity by perforin antisense oligonucleotides. EMBO J 9:3815-3819, 1990
64. LIU CC, RAFII S, GRANELLI-PIPERNO A, TRAPANI JA, YOUNG JDE: Perforin and serine esterase gene expression in stimulated human T cells. J Exp Med 170:2105-2118, 1989
65. KAGI D, LEDERMANN B, BURKI K, SEILER P, ODERMATT B, OLSEN KJ, PODACK ER, ZINKERNAGEL RM, HENGARTNER H: Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. Nature 369:31-37, 1994
66. HENKART PA: Lymphocyte-mediated cytotoxicity: two pathways and multiple effector molecules. Immunity 1:343-346, 1994
67. BURKE G: Unlocking the secrets of CTL and NK cells. Immunology 16:343-346, 1995
68. KIRKMAN RL, BARRETT LV, GAULTON GN, KELLEY VE, YTHIER A, STROM TB: Administration of an anti-IL-2 receptor monoclonal antibody prolongs cardiac allograft survival in mice. J Exp Med 162:358-362, 1985
69. KUPIEC-WEGLINSKI JW, DIAMANTSTEIN T, TILNEY NL, STROM TB: Therapy with monoclonal antibody to IL-2 receptor spares suppressor T cells and prevents or reverses acute allograft rejection in rats. Proc Natl Acad Sci USA 83:2624-2627, 1986
70. KIRKMAN RL, SHAPIRO ME, CARPENTER CB, MCKAY DB, MILFORD IL, RAMOS IL, TILNEY NL, WALDMANN TA, ZIMMERMANN CE, STROM TB: A randomized prospective trial of anti-Tax monoclonal antibody in human renal transplantation. Transplantation 51:107-113, 1991
71. SOULILLOU JP, CANTAROVICH D, LEMAUFF B, GIRAL M, ROBILLARD N, HOURMANT M, HIRN M, JACQUES Y: Randomized controlled trial of a monoclonal antibody against the interleukin-2 receptor (33B3.1) as compared with rabbit antithymocyte globulin for prophylaxis against rejection of renal allografts. N Engl J Med 322:1175-1182, 1990
72. O'CONNEL P, PACHECO-SILVA A, NICKERSON P, MUGGIA RA, BASTOS M, RUBIN KELLEY V, STROM TB: Unmodified pancreatic islet allograft rejection results in the preferential expression of certain T cell activation transcripts. J Immunol 150:1093-1104, 1993
73. WHICHER JT, EVANS SW: Cytokines in disease. Clin Chem 36:1269-1281, 1990
74. KAI K, LEE F, MIYAJIMA A, MIYATAKE S, ARAI N, YOKOTA T: Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem 59:783-836, 1990
75. PAUL WE: Interleukin-4: a prototypic immunoregulatory cytokine. Blood 77:1859-1870, 1991
76. TAKEUCHI T, LOWRY RP, KONIECZNY B: Heart allografts in murine systems. The differential activation of TH2-like effector cells in peripheral tolerance. Transplantation 53:1281-1294, 1992
77. STREET NE, MOSMANN TR: Functional diversity of T lymphocytes due to secretion of different cytokine patterns. FASEB J 5:171-177, 1991
78. MOSMANN TR, MOORE KW: The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today 12:A49-A53, 1991
79. DEL PRETE G, DE CARLI M, ALMERIGOGNA F, GIUDIZI MG, BIAGIOTTI R, ROMAGNANI S: Human IL-10 is produced by both type 1 helper (TH1) and type 2 helper (TH2) T cell clones and inhibits their antigen-specific proliferation and cytokine production. J Immunol 150:353-360, 1993
80. CHEN WF, ZLOTNIK A: Interleukin 10: a novel cytotoxic T cell differentiation factor. J Immunol 147:528-534, 1991
81. GO NF, CASTLE BE, BARRETT R, KASTELEIN R, DANG W, MOSMANN TR, MOORE KW, HOWARD M: Interleukin-10, a novel B cell stimulatory factor: unresponsiveness of X-chromosome like immunodeficiency B cells. J Exp Med 172:1625-1631, 1990
82. MOSMANN TR, COFFMAN RL: TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 7:145-173, 1989
83. HAANEN JB, DE WAAL MALEVIJT R, RES PC, KRAAKMAN EM, OTTENHOFF TH, DE VRIES RR, SPITS H: Selection of a human T helper type 1-like T-cell subset by mycobacteria. J Exp Med 174:583-592, 1991
84. SALGAME P, ABRAMS JS, CLAYBERGER C, GOLDSTEIN H, CONVIT J, MODLIN RL, BLOOM BR: Differing lymphokine profiles of functional subsets of human CD4 and CD8 T-cell clones. Science 254:279-282, 1991
85. PARRONCHI P, MACCHIA D, PICCINNI M, BISWAS P, SIMONELLI C, MAGGI E, RICCI M, ANSARI AA, ROMAGNANI S: Allergen and bacterial antigen-specific T-cell clones established from atopic donors show a different profile of cytokine production. Proc Natl Acad Sci USA 88:4538-4542, 1991
86. MAGGI E, BISWAS P, DEL PRETE G, PARONCHI P, MACCIA D, SIMONELLI C, EMMI L, DE CARLI M, TIRI A, RICCI M, ROMAGNANI S: Accumulation of TH-2-like helper T cells in the conjunctiva of patients with vernal conjunctivitis. J Immunol 146:1169-1174, 1991
87. SHER A, COFFMAN RI: Regulation of immunity to parasites by T cell and T cell-derived cytokines. Annu Rev Immunol 10:385-409, 1992
88. BLOOM BR, MODLIN RL, SALGAME P: Stigma variations: observations on suppressor T cells and leprosy. Annu Rev Immunol 10:453-488, 1992
89. GOLDMAN M, VELU T: Inlerleukin-10 and its implications for immunopathology, in Advances in Nephrology, edited by GRÜNFELD J-P, BACH JF, DREISS H, MAXWELL MH, St. Louis, Mosby, 1995, pp 79-85
90. NICKERSON P, STEURER W, STEIGER J, ZHENG X, STEELE AW, STROM TB: Cytokines and the Th1/Th2 paradigm in transplantation. Curr Opin Immunol 6:757-764, 1994
91. LI B, SEHAJPAL PK, KHANNA A, VLASSARA H, CERAMI A, STENZEL KH, SUTMANTHIRAN M: Differential regulation of transforming growth factor-beta and interleukin-2 genes in human T-cells: Demonstration by usage of novel competitor DNA constructs in the quantitative polymerase chain reaction. J Exp Med 174:1259-1262, 1991
92. PAVALAKIS M, LIPMAN ML, STROM TB: Intragraft T cell receptor transcript expression in human renal allografts. J Am Soc Nephrol 6:281-285, 1995
93. SCHREIBER SC: Immunophilin-sensitive protein phosphatase activation in cell signaling pathways. Cell 70:365-368, 1992
94. KNUDSEN PJ, DINARELLO CA, STROM TB: Glucocorticoids inhibit transcription and post-transcriptional expression of interleukin-1. J Immunol 139:4129-4134, 1987
95. ZANKER B, WALZ G, WIEDER KJ, STROM TB: Evidence that glucocorticosteroids block expression of the human interleukin-6 gene by accessory cells. Transplantation 49:183-185, 1990
96. ARYA SK, WONG-STAAL F, GALLO RC: Dexamethasone mediated inhibition of T-cell growth factor and gamma interferon messenger RNA. J Immunol 133:273-276, 1984
97. ALMAWI WY, LIPMAN ML, STEVENS AC, ZANKER B, HADRO ET, STROM TB: Abrogation of glucocorticosteroid-mediated inhibition of T-cell proliferation by the synergistic action of IL-1, IL-6, and IFN. J Immunol 146:3523-3527, 1991
98. VACCA A, FELLI MP, FARINA AR, MARTINOTTI S, MARODER M, SCREPANTI I, MECO D, PETRANGELI E, FRATI L, GULINO A: Glucocorticoid receptor-mediated suppression of the interleukin-2 gene expression through impairment of the cooperativity between nuclear factor of activated T-cells and AP-1 enhancer elements. J Exp Med 175:637-646, 1992
99. YANG-YEE HF, CHAMBARD JC, SUN YL, SMEAL T, SCHMIDT TJ, DROUIN J, KARIN M: Transcriptional interference between cp-Jun and the glucocorticoid receptor: Mutual inhibition of DNA binding due to direct protein-protein interaction. Cell 62:1205-1215, 1990
100. PALVOGIANNI F, RAPTIS A, AHUJA SS, NAJJAR SM, BOUMPAS DT: Negative transcriptional regulation of human interleukin-2 (IL-2) gene by glucocorticoids through interference with nuclear transcription factors AP-1 and NF-AT. J Clin Invest 91:1481-1487, 1993
101. SCHEINMAN RI, COGSWELL PG, LOFOUIST AK, BALDWIN AS JR: Role of transcriptional activation of IκBα in mediation of immunosuppression by glucocorticoids. Science 270:283-286, 1995
102. AUPHAN N, DIDONATO JA, ROSETTE C, HELMBERG A, KARIN M: Immunosuppression by glucocorticoids: Inhibition of NFκB activity through induction of IκB synthesis. Science 270:286-290, 1995
103. ELION GB: Biochemistry and pharmacology of purine analogues. Fed Proc 26:898-904, 1967
104. MORRIS RE, WANG J: Comparison of the immunosuppressive effects of mycophenolic acid and the morpholinethal ester of mycophenolic acid (RS-61443) in recipients of heart grafts. Transplant Proc 23:493-506, 1991
105. ALLISON AC, EUGUI EM: Immunosuppressive and other effects of mycophenolic acid and an ester prodrug, mycophenolate mofetil. Immunol Rev 136:5-19, 1993
106. EUROPEAN MYCOPHENOLATE MOFETIL COOPERATIVE STUDY GROUP: Placebo-controlled study of mycophenolate mofetil combined with cyclosporin and corticosteroids for prevention of acute rejection. Lancet 345:1321-1325, 1995
107. SOLLINGER HW, FOR THE U.S. RENAL TRANSPLANT MYCOPHENOLATE MOFETIL STUDY GROUP: Mycophenolate mofetil for the prevention of acute rejection in primary cadaveric renal allograft recipients. Transplantation 60:225-232, 1995
108. TURKA LA, DAYTON J, SINCLAIR G, THOMPSON CB, MITCHELL BS: Guanine ribonucleotide depletion inhibits T-cell activation: Mechanism of action of the immunosuppressive drug mizoribine. J Clin Invest 87:940-948, 1991
109. KOKADO Y, ISHIBAHI M, JIANG H: Low dose ciclosporin, mizoribine and prednisone in renal transplantation: A new triple drug therapy. Clin Transplant 4:191-197, 1990
110. MORRIS RE: Rapamycins: antifungal, antitumor, antiproliferative, and immunosuppressive macrolides. Transplant Rev 6:39-87, 1992
111. SEHGAL SN, CAMARDO JS, SCAROLA JA, MAIDA BT: Rapamycin (sirolimus, rapamune). Curr Opin Nephrol Hvpertens 4:482-487, 1995
112. CHUNG J, KUO CJ, CRABTREE GR, BLENIS J: Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kD S6 protein kinases. Cell 69:1227-1236, 1992
113. HEITMAN J, MOVVA NR, HALL MN: Targets for cell cycle arrest by the immunosuppressant rapamycin in yeast. Science 253:905-909, 1991
114. SABATINI DM, ERDJUMENT BROMAGE H, LUI M, TEMPST P, SYNDER SH: Raft-1: A mammalian protein that binds to FKBP 12 in a rapamycin dependent fashion and is homologous to yeast TORS. Cell 78:35-43, 1994
115. LAI JH, TAN H: CD28 signaling causes a sustained down-regulation of I kappa B alpha which can be prevented by the immunosuppressant rapamycin. J Biol Chem 269:30077-30080, 1994
116. GREGORY CR, HUANG X, PRATT RE, DZAU VJ, SHORTHOUSE R, BILLINGHAM ME, MORRIS RE: Treatment with rapamycin and mycophenolic acid reduces arterial intimai thickening produced by mechanical injury and allows endothelial replacement. Transplantation 59:655-661, 1995
117. MURGIA MG, JORDAN S, KAHAN BD: The side effect profile of sirolimus: A phase I study in quiescent cyclosporine-prednisone-treated renal transplant patients. Kidney Int 49:209-216, 1996
118. TAKEUCHI T, IINUMA H, KUNIMOTO S, MASUDA T, ISHIZUKA M, TAKEUCHI M, HAMADA M, NAGANAWA H, KONDO S, UMEZAWA H: A new antitumor antibiotic, spergualin: isolation and antitumor activity. J Antibiot (Tokyo) 34:1619-1621, 1981
119. NADLER SG, TEPPER MA, SCHACTER B, MAZZUCCO CE: Interaction of the immuno-suppressant deoxyspergualin with a member of the Hsp70 family of heat shock proteins. Science 258:484-486, 1992
120. HELDERMAN JH: Review and preview of anti-T-cell antibodies. Transplant Proc 27:8-9, 1995
121. NORMAN DJ: Antilymphocyte antibodies in the treatment of allograft rejection: targets, mechanisms of action, monitoring, and efficacy. Semin Nephrol 12:315-324, 1992
122. FILO RS, SMITH EJ, LEAPMAN SB: Therapy of acute cadaveric renal allograft rejection with adjunctive antithymocyte globulin. Transplantation 30:445-449, 1980
123. ORTHO MULTICENTER TRANSPLANT STUDY GROUP: A randomized clinical trial of OKT3 monoclonal antibody for acute rejection of cadaveric renal transplants. N Engl J Med 313:337-342, 1985
124. SUTHANTHIRAN M, FOTINO M, RIGGIO RR, CHEIGH JS, STENZEL KH: OKT3-associated adverse reactions: Mechanistic basis and therapeutic options. Am J Kidney Dis 14:39-44, 1989
125. VINCENTI FG, VASCONCELOS M, BIRNBAUM HL, TOMLANOVICH SJ, AMEND WJC JR, MELZER JS, SNYDER JP: Pentoxifylline reduces the first-dose reactions following OKT3. Transplant Proc 25:57-59, 1993
126. FIRST MR, SCHROEDER TJ, HARIHARAN S, WEISKITTEL P: Reduction of the initial febrile response to OKT3 with indomethacin. Transplant Proc 25:52-54, 1993
127. CHATENOUD L: OKT3-induced cytokine-release syndrome: Preventive effect of anti-tumor necrosis factor monoclonal antibody. Transplant Proc 25:47-51, 1993
128. WAID TH, LUCAS BA, THOMPSON JS, BROWN SA, MUNCH L, PREBECK RJ, JEZEK D: Treatment of acute cellular rejection with T10B9.1A-31 or OKT3 in renal allograft recipients. Transplantation 53:80-86, 1992
129. YOSHIMURA N, TAKAHASHI K, ISHIBASHI M: Treatment of acute cellular rejection with BMA031 in renal transplant recipients - a multi centered trial in Japan (abstract). Proc Am Soc Transplant Surg, 1992, p 63
130. GOODMAN ER, HARDY MA: Transplantation 1992: The year in review, in Clinical Transplants 1992, edited by TERASAKI PI, CECKA JM, Los Angeles, UCLA Tissue Typing Laboratory, 1993, pp 285-297
131. ETTINGER RM, YADIN O: The potential role of therapeutic antibodies in the regulation of rejection. Transplant Proc 27:13-17, 1995
132. QIN L, CHAVIN KD, LIN J, YAGITA H, BROMBERG JS: Anti-CD2 receptor and anti-CD2 ligand (CD48) antibodies synergize to prolong allograft survival. J Exp Med 179:341-346, 1994
133. TURKA LA, LINSLEY H, LIN W, BRADY W, LEIDEN JM, WEI RQ, GIBSON ML, ZHENG XG, MYRDAL S, GORDON D: T cell activation by the CD28 ligand B7 is required for cardiac allograft rejection in vivo. Proc Natl Acad Sci USA 89:11102-11105, 1992
134. QUEEN C, SCHNEIDER WP, SELICK HE, PAYNE PW, LANDOLFI NF, DUNCAN JF, AVDALOVIC NM, LEVITT M, JUNGHANS RP, WALDMANN TA: A humanized antibody that binds to the interleukin 2 receptor. Proc Natl Acad Sci USA 86:10029-10033, 1989
135. NOSSAL GJ: Immunological tolerance: Collaboration between antigen and lymphokines. Science 245:147-153, 1989
136. SUTHANTHIRAN M, STROM TB: Immunology and genetics of transplantation, in Textbook of Nephrology (3rd ed), edited by MASSRY SG, GLASSOCK RJ, Baltimore, Williams & Wilkins, 1994, pp 629-637
137. WATERHOUSE P, PENNINGER JM, TIMMS E, WAKEHAM A, SHAHINIAN A, LEE KP, THOMPSON CB, GRIESSER H, MAK TW: Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270:985-988, 1995
138. SAYEGH MH, TURKA LA: T cell co-stimulatory pathways: promising novel targets of immunosuppression and tolerance induction. J Am Soc Nephrol 6:1143-1150, 1995
139. LARSEN CP, ALEXANDER DZ, HOLLENBAUGH D, ELWOOD ET, RITCHIE SC, ARUFFO A, HENDRIX R, PEARSON TC: CD40-gp39 interactions play a critical role during allograft rejection. Transplantation 61:4-9, 1996
140. NOSSAL GJ: Molecular and cellular aspects of immunologic tolerance. Eur J Biochem 202:729-737, 1991
141. KRONENBERG M: Self-tolerance and autoimmunity. Cell 65:537-542, 1991
142. MILLER JF, FLAVELL RA: T-cell tolerance and autoimmunity in transgenic models of central and peripheral tolerance. Curr Opin Immunol 6:892-899, 1994
143. SACHS DH: CCETS Basic Science Lecture. Transplantation Tolerance. Ann Thorac Surg 56:1221-1227, 1993
144. POSSELT AM, BARKER CF, TOMASZEWSKI JE, MARKMANN JF, CHOTI MA, NAJI A: Induction of donor-specific unresponsiveness by intrathymic islet transplantation. Science 249:1293-1295, 1990
145. STREILEIN JW: Unraveling immune privilege. Science 270:1158-1159, 1995
146. GRIFFITH TS, BRUNNER T, FLETCHER SM, GREEN DR, FERGUSON TA: Fas ligand-induced apoptosis as a mechanism of immune privilege. Science 270:1189-1192, 1995
147. BELLGRAU D, GOLD D, SELAWRY H, MOORE J, FRANZUSOFF A, DUKE RC: A role for CD95 ligand in preventing graft rejection. Nature 377:630-632, 1995
148. SOULILLOU J-P: Nephrology Forum: Relevant targets for therapy with monoclonal antibodies in allograft transplantation. Kidney Int 46:540-553, 1994
149. KIMBALL A, PESCOVITZ MD, BOOK BK, NORMAN DJ: Reduced human IgG anti-ATGAM antibody formation in renal transplant recipients receiving mycophenolate mofetil. Transplantation 60:1379-1383, 1995
150. WOGENSEN L, LEE M-S, SARVETNICK N: Production of IL-10 by islet cells accelerates immune-mediated destruction of β cells in nonobese diabetic mice. J Exp Med 179:1379-1380, 1994
151. MORITANI M, YOSHIMOTO K, TASHIRO K, HASHIMOTO C, MIYAZAKI J, II S, KUDO E, IWAHANA H, HAYASHI Y, SANO T, ITAKURA M: Transgenic expression of IL-10 in pancreatic islet a cells accelerates autoimmune insulitis and diabetes in non-obese diabetic mice. Int Immunol 6:1927-1936, 1994
152. LEE M-S, WOGENSEN L, SHIZURU J, OLDSTONE MBA, SARVETNIK N: Pancreatic islet production of murine IL-10 does not inhibit immune-mediated tissue destruction. J Clin Invest 93:1332-1384, 1994
153. ZHENG XX, STEELE AW, NICKERSON PW, STEURER W, STEIGER J, STROM TB: Administration of noncytolytic IL-10/Fc in murine models of lipopolysaccharide-induced septic shock and allogeneic islet transplantation. J Immunol 154:5590-5600, 1995
154. CARDENAS ME, LIM E, HEITMAN J: Mutations that perturb cyclophilin A ligand binding pocket confer cyclosporin A resistance in Saccharomyces cerevisiae. J Biol Chem 270:20997-21002, 1995
155. JORDAN ML, SHAPIRO R, VIVAS CA, SCANTLEBURY VP, RHANDHAWA P, CARRIERI G, MCCAULEY J, DEMETRIS AJ, TZAKIS A, FUNG JJ, ET AL: FK506 "rescue" for resistant rejection of renal allografts under primary cyclosporine immunosuppression. Transplantation 57: 860-865, 1994
156. FUNG JJ, STARZL TE: FK506 in solid organ transplantation. Ther Drug Monit 17:592-595, 1995
157. GRUESSNER RW, BURKE GW, STRATTA R, SOLLINGER H, BENEDETTI E, MARSH C, STOCK P, BOUDREAUX JP, MARTIN M, DRANSTVEIT MB, SUTHERLAND DE, GRUESSNER A: A multicenter analysis of the first experience with FK506 for induction and rescue therapy after pancreas transplantation. Transplantation 61:261-273, 1996
158. NARAGHI RM, SMITH D, SHAPIRO R, VIVAS CA, GRITSCH HA, SCANTLEBURY VP, RANDHAWA P, DEMETRIS AJ, STARZL TE, FUNG J, JORDAN ML: Long-term follow-up of tacrolimus rescue therapy for renal allograft rejection (abstract). 15th Annu Mtg, Am Soc Transplant Physicians, Dallas, TX, 1996, p 151
159. STEELE DM, HULLETT DA, BECHSTEIN WO, KOWALSKI J, SMITH LS, KENNEDY E, ALLISON AC, SOLLINGER HW: Effects of immunosuppressive therapy on the rat aortic allograft model. Transplant Proc 25:754-755, 1993
160. AZUMA H, BINDER J, HEEMAN U, SCHMID C, TULLIUS SC, TILNEY NL: Effects of RS61443 on functional and morphological changes in chronically rejecting rat kidney allografts. Transplantation 59:460-466, 1995
161. NADEAU KC, AZUMA H, TILNEY NL: Sequential cytokine dynamics in chronic rejection of rat renal allografts. Roles for cytokines RANTES and MCP-1. Proc Natl Acad Sci USA 92:8729-8733, 1995
162. KHANNA A, LI B, STENZEL KH, SUTHANTHIRAN M: Regulation of new DNA synthesis in mammalian cells by cyclosporine: demonstration of a transforming growth factor β dependent mechanism of inhibition of cell growth. Transplantation 57:577-582, 1994
163. ROBERTS AB, SPORN MB: Physiological actions and clinical applications of transforming growth factor-β (TGF-β). Growth Factors 8:1-9, 1993
164. BORDER WA, NOBEL NA: Transforming growth factor-β in tissue fibrosis. N Engl J Med 331:1286-1292, 1994
165. WOLF G, THAISS R, STAHL RAK: Cyclosporine stimulates expression of transforming growth factor- β in renal cells. Transplantation 60:237-241, 1995
166. SHEHATA M, COPE GH, JOHNSON TS, RAFTERY AT, EL NAHAS AM: Cyclosporine enhances the expression of TGF-β in the juxtaglomerular cells of the rat kidney. Kidney Int 48:1487-1496, 1995
167. 1 in experimental chronic cyclosporine nephropathy. Kidney Int 49:1141-1151, 1996
168. SAYEGH MH, AKALIN E, HANCOCK WW, RUSSELL ME, CARPENTER CB, LINSLEY PS, TURKA LA: CD28-B7 blockade after alloantigenic challenge in vivo inhibits TH1 cytokine but spares TH2. J Exp Med 181:1869-1874, 1995
169. STEIGER J, NICKERSON PW, STEURER W, MOSCOVITCH-LOPATIN M, STROM TB: IL-2 knockout recipient mice reject islet cell allografts. J Immunol 155:489-498, 1995
170. FIORENTINO DF, BOND MW, MOSMANN TR: Two types of mouse T helper cell. IV: Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 170:2081-2095, 1993
171. JENKINS DA, WOJTACHA DR, SWAN P, FLEMING S, CUMMING AD: Renal expression of interleukin-2 receptor mRNA in patients with crescentic glomerulonephritis. Nephron (Switzerland) 71:303-308, 1995
172. NEALE TJ, RUGER BM, MACAULAY H, DUNBAR PR, HASAN O, BOURKE A, MURRAY-MCINTOSH RP, KITCHING AR: Tumor necrosis factor-alpha is expressed by glomerular visceral epithelial cells in human membranous nephropathy. Am J Pathol 146:1444-1454, 1995
173. SHIKATA K, MAKINO H, MORIOKA S, KASHITANI T, HIRATA K, OTA Z, WADA J, KANWAR YS: Distribution of extracellular matrix receptors in various forms of glomerulonephritis. Am J Kidney Dis 25:680-688, 1995
174. 1 mRNA in patients with diabetes mellitus. Kidney Int 49:1120-1126, 1996
175. IWANO M, AKAI Y, FUJII Y, DOHI Y, MATSUMURA N, DOHI K: Intraglomerular expression of transforming growth factor-beta (TGF-beta 1) mRNA in patients with glomerulonephritis: quantitative analysis by competitive polymerase chain reaction. Clin Exp Immunol 97:309-314, 1994
176. YAMAMOTO T, NOBLE NA, COHEN AH, NAST CC, HISHIDA A, GOLD LI, BORDER WA: Expression of transforming growth factor-β isoforms in human glomerular diseases. Kidney Int 49:461-469, 1996
177. TIPPING PG, ERLICH JH, APOSTOLOPOULOS J, MACKMAN N, LOSKUTOFF D, HOLDSWORTH SR: Glomerular tissue factor expression in crescentic glomerulonephritis. Correlations between antigen, activity, and mRNA. Am J Pathol 147:1736-1748, 1995
178. LAN HY, NIKOLIC-PATERSON DJ, MU W, VANNICE JL, ATKINS RC: Interleukin-1 receptor antagonist halts the progression of established crescentic glomerulonephritis in the rat. Kidney Int 47:1301-1309, 1995
179. ATKINS RC: Nephrology Forum: Interleukin-1 in crescentic glomerulonephritis. Kidney Int 48:576-586, 1995
180. LAKKIS FG, KONIECZNY BT, LOWRY RP, LINSLEY PS, ALEXANDER DZ, PEARSON TC, LARSEN CP: Prolonged cardiac allograft survival in IL-4 gene-knockout mice treated with CTLA4Ig (abstract). 15th Annu Mtg, Am Soc Transplant Physicians, Dallas, TX, 1996, p 119
181. KONIECYZNY BT, SALEEM S, LOWRY RP, LAKKIS FG: Vigorous cardiac allograft rejection in IFNy gene-knockout mice (abstract). 15th Annu Mtg, Am Soc Transplant Physicians, Dallas, TX. 1996, p 171
182. KAWAI K, SHAHINIAN A, MAK TW, OHASHI PS: Skin allograft rejection in CD28-deficient mice. Transplantation 61:352-355, 1996